Merck Q2 sales $10.9 billionStaff writer ▼ | July 30, 2014
Merck, known as MSD outside the United States and Canada, announced financial results for the second quarter of 2014. Worldwide sales were $10.9 billion, a decrease of 1 percent compared with the second quarter of 2013, with no net impact from foreign exchange.
Some up, some down Mixed results of pharma products sales
Combined sales of Zetia and Vytorin, medicines for lowering LDL cholesterol, increased 6 percent to $1.1 billion in the second quarter, including a 1 percent positive impact from foreign exchange. The growth was driven by higher sales of Zetia in the United States, reflecting wholesaler purchases and price increases.
Combined sales of Remicade and Simponi, treatments for inflammatory diseases, grew 21 percent to $781 million in the second quarter, including a 6 percent positive impact from foreign exchange.
Worldwide sales of Isentress, an HIV integrase inhibitor for use in combination with other antiretroviral agents for the treatment of HIV-1 infection, increased 10 percent to $453 million in the second quarter. The increase was driven by strong growth in Europe and the emerging markets.
Animal Health sales totaled $872 million for the second quarter of 2014, a 2 percent increase compared with the second quarter of 2013, including a 1 percent negative impact due to foreign exchange. The growth was primarily driven by Bravecto (fluralaner), a chewable tablet that kills fleas and ticks in dogs for up to 12 weeks, which launched in Europe and the United States, as well as higher sales in poultry and aqua products.
This growth was partially offset by the loss of sales of zilmax (zilpaterol hydrochloride), a feed supplement for beef cattle. The company decided last year to voluntarily suspend sales of ZILMAX in the United States and Canada. Excluding the impact of the Zilmax sales suspension, Animal Health sales increased 9 percent in the second quarter. ■